NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
Clinical Trials
5 trialsNCT02747537 2019-09-09
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Washington University School of Medicine
Phase 2 Withdrawn
NCT00810394 2018-01-10
Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
University of California, Davis
Phase 2 Completed
NCT00107432 2013-06-05
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
National Cancer Institute (NCI)
Phase 2 Completed
NCT00794859 2009-08-04
SMS
King's College London
Phase 2 Unknown